Skip to main content

CLL

Conference Coverage
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
Videos
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
01/06/2015
Periorbital Richter Syndrome Mark Gorman, MRCS, MSc,a Julia Ruston, MRCS,b and Sarath Vennam, BMBSa aDivision of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom; and bDivision of Plastic Surgery,...
Periorbital Richter Syndrome Mark Gorman, MRCS, MSc,a Julia Ruston, MRCS,b and Sarath Vennam, BMBSa aDivision of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom; and bDivision of Plastic Surgery,...
Periorbital Richter...
01/06/2015
ePlasty